Attached files
file | filename |
---|---|
8-K - FORM 8-K - ANADYS PHARMACEUTICALS INC | a56323e8vk.htm |
EX-1.1 - EX-1.1 - ANADYS PHARMACEUTICALS INC | a56323exv1w1.htm |
EX-5.1 - EX-5.1 - ANADYS PHARMACEUTICALS INC | a56323exv5w1.htm |
EX-99.1 - EX-99.1 - ANADYS PHARMACEUTICALS INC | a56323exv99w1.htm |
Exhibit 99.2
ANADYS PHARMACEUTICALS, INC. ANNOUNCES
$12.5 MILLION REGISTERED DIRECT OFFERING
$12.5 MILLION REGISTERED DIRECT OFFERING
San Diego, May 26, 2010 Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it has
entered into definitive agreements with certain institutional investors to raise approximately
$12.5 million in gross proceeds in a registered direct offering through the sale of a total of
5,813,954 shares of its common stock at an offering price of $2.15 per share. Anadys estimates that
net proceeds from the offering will be approximately
$11.3 million, after deducting placement agents fees and estimated offering expenses. The closing of the transaction is scheduled to occur on June
1, 2010, subject to the satisfaction of customary closing conditions. All of the shares of common
stock were offered pursuant to an effective shelf registration statement. Proceeds from the
transaction will be used for general corporate purposes.
Lazard Capital Markets LLC served as the lead placement agent and Piper Jaffray & Co. served as the
co-placement agent for the offering.
A shelf registration statement relating to the shares of common stock issued in the offering has
been filed with, and declared effective by, the Securities and Exchange Commission (the SEC). A
prospectus supplement relating to the offering will be filed with the SEC. Copies of the prospectus
supplement and accompanying prospectus, when available, may be
obtained at the SECs website at http://www.sec.gov or from the offices of Lazard
Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York, NY, 10020. This press
release shall not constitute an offer to sell or a solicitation of an offer to buy any shares of
common stock. No offer, solicitation or sale will be made in any jurisdiction in which such offer,
solicitation or sale is unlawful.
About Anadys
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by
developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C
represents a large unmet medical need in which meaningful improvements in treatment outcomes may be
attainable with the introduction of new medicines. The Company is developing ANA598, a non-
nucleoside polymerase inhibitor for the treatment of hepatitis C. In an ongoing Phase II study, the
Company has completed 12 weeks of dosing ANA598 added to current standard of care. The Company has
also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous
interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.
Safe Harbor Statement
Statements in this press release that are not strictly historical in nature constitute
forward-looking statements. Such statements include, but are not limited to, references to
Anadys financing plans and issuance of securities, the amount of proceeds from the offering, the
closing of the offering, the use of proceeds from the offering, Anadys development programs and
Anadys ability to develop novel medicines in the area of hepatitis C. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors, which may cause
Anadys actual results to be materially different from historical results or from any results
expressed or implied by such forward-looking statements. For example, there are risks associated
with investors fulfilling their obligations to purchase the securities and Anadys ability to
satisfy its conditions to close the offering. In addition, the results of preclinical and early
clinical studies may not be predictive of future results, and Anadys cannot provide any assurances
that ANA598 will not have unforeseen safety issues, will have favorable results in future clinical
trials or will receive regulatory approval. Risk factors that may cause actual results to differ
are discussed in Anadys SEC filings. All forward-looking statements are qualified in their
entirety by this cautionary statement. Anadys is providing this information as of this date and
does not undertake any obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise.